N. Anthony Coles Jr., M.P.H.
Net Worth

Last updated:

What is N. Anthony Coles Jr., M.P.H. net worth?

The estimated net worth of Dr. N. Anthony Coles Jr., M.P.H. is at least $34,117,319 as of 1 Jul 2024. He has earned $30,397,319 from insider trading and has received compensation worth at least $3,720,000 in Cerevel Therapeutics Holdings, Inc..

What is the salary of N. Anthony Coles Jr., M.P.H.?

Dr. N. Anthony Coles Jr., M.P.H. salary is $1,240,000 per year as Chief Executive Officer & Executive Chairman in Cerevel Therapeutics Holdings, Inc..

How old is N. Anthony Coles Jr., M.P.H.?

Dr. N. Anthony Coles Jr., M.P.H. is 65 years old, born in 1960.

What stocks does N. Anthony Coles Jr., M.P.H. currently own?

As insider, Dr. N. Anthony Coles Jr., M.P.H. owns shares in one company:

Company Title Shares Price per share Total value
Cerevel Therapeutics Holdings, Inc. (CERE) Chief Executive Officer & Executive Chairman 25,928 $0 $0

What does Cerevel Therapeutics Holdings, Inc. do?

Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures in epilepsy or focal epilepsy, as well as in phase 1 trial to treat acute anxiety. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; CVL-936, a selective dopamine D3-preferring antagonist, which is in Phase I clinical trial for the treatment of substance use disorder; CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder; and CVL-047, selective PDE4 inhibitor for the treatment of major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and an LRRK2 inhibitor program to address disease progression in Parkinson's. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.

CERE logo
CERE
Cerevel Therapeutics Holdings, Inc.

N. Anthony Coles Jr., M.P.H. insider trading

Cerevel Therapeutics Holdings, Inc.

Dr. N. Anthony Coles Jr., M.P.H. has made 28 insider trades between 2022-2024, according to the Form 4 filled with the SEC. Most recently he sold 25,000 units of CERE stock worth $1,029,525 on 1 Jul 2024.

The largest trade he's ever made was exercising 61,401 units of CERE stock on 3 Nov 2023. As of 1 Jul 2024 he still owns at least 25,928 units of CERE stock.

Transaction Date Security Shares Price per share Total value Source
Sale
Common Stock 25,000 $41.18 $1,029,525
Option
Common Stock 25,000 $3.5 $87,500
Option
Stock Option (Right to Buy) 25,000 $3.5 $87,500
Sale
Common Stock 50,000 $40.61 $2,030,500
Option
Common Stock 50,000 $3.5 $175,000
Option
Stock Option (Right to Buy) 50,000 $3.5 $175,000
Option
Stock Option (Right to Buy) 50,000 $3.5 $175,000
Option
Common Stock 50,000 $3.5 $175,000
Sale
Common Stock 50,000 $42.1 $2,105,150
Option
Common Stock 50,000 $3.5 $175,000
Option
Stock Option (Right to Buy) 50,000 $3.5 $175,000
Sale
Common Stock 50,000 $42.33 $2,116,650
Sale
Common Stock 50,000 $41.01 $2,050,550
Option
Stock Option (Right to Buy) 50,000 $3.5 $175,000
Option
Common Stock 50,000 $3.5 $175,000
Sale
Common Stock 50,000 $41.16 $2,057,900
Option
Stock Option (Right to Buy) 50,000 $3.5 $175,000
Option
Common Stock 50,000 $3.5 $175,000
Sale
Common Stock 2,506 $41.54 $104,109
Option
Common Stock 15,440 N/A N/A
Option
Restricted Stock Units 15,440 N/A N/A
Option
Stock Option (Right to Buy) 50,000 $3.5 $175,000
Sale
Common Stock 50,000 $42.24 $2,111,800
Option
Common Stock 50,000 $3.5 $175,000
Sale
Common Stock 22,824 $25.13 $573,453
Option
Common Stock 22,824 $3.5 $79,884
Option
Stock Option (Right to Buy) 22,824 $3.5 $79,884
Option
Stock Option (Right to Buy) 100 $3.5 $350
Sale
Common Stock 100 $25.16 $2,516
Option
Common Stock 100 $3.5 $350
Sale
Common Stock 27,076 $25.02 $677,550
Option
Common Stock 27,076 $3.5 $94,766
Option
Stock Option (Right to Buy) 27,076 $3.5 $94,766
Sale
Common Stock 61,401 $25.43 $1,561,489
Option
Stock Option (Right to Buy) 61,401 $3.5 $214,904
Option
Common Stock 61,401 $3.5 $214,904
Option
Stock Option (Right to Buy) 38,599 $3.5 $135,097
Option
Common Stock 38,599 $3.5 $135,097
Sale
Common Stock 38,599 $25.19 $972,232
Sale
Common Stock 50,000 $24.07 $1,203,400
Option
Common Stock 50,000 $3.5 $175,000
Option
Stock Option (Right to Buy) 50,000 $3.5 $175,000
Option
Common Stock 50,000 $3.5 $175,000
Option
Stock Option (Right to Buy) 50,000 $3.5 $175,000
Sale
Common Stock 50,000 $30.03 $1,501,350
Sale
Common Stock 50,000 $32.6 $1,630,050
Option
Stock Option (Right to Buy) 50,000 $3.5 $175,000
Option
Common Stock 50,000 $3.5 $175,000
Option
Common Stock 50,000 $3.5 $175,000
Option
Stock Option (Right to Buy) 50,000 $3.5 $175,000
Sale
Common Stock 37,568 $31.36 $1,178,283
Sale
Common Stock 12,132 $31.76 $385,288
Sale
Common Stock 300 $32.93 $9,879
Sale
Common Stock 50,000 $25.06 $1,253,150
Option
Common Stock 50,000 $3.5 $175,000
Option
Stock Option (Right to Buy) 50,000 $3.5 $175,000
Option
Common Stock 3,000 $3.5 $10,500
Sale
Common Stock 3,000 $27.19 $81,570
Option
Stock Option (Right to Buy) 3,000 $3.5 $10,500
Sale
Common Stock 47,000 $27.11 $1,274,358
Option
Common Stock 47,000 $3.5 $164,500
Option
Stock Option (Right to Buy) 47,000 $3.5 $164,500
Option
Common Stock 50,000 $3.5 $175,000
Sale
Common Stock 7,942 $33.58 $266,653
Option
Stock Option (Right to Buy) 50,000 $3.5 $175,000
Sale
Common Stock 42,058 $33.04 $1,389,765
Sale
Common Stock 500 $30.73 $15,366
Sale
Common Stock 49,500 $29.93 $1,481,486
Option
Stock Option (Right to Buy) 50,000 $3.5 $175,000
Option
Common Stock 50,000 $3.5 $175,000
Sale
Common Stock 5,145 $27.09 $139,393
Option
Common Stock 50,000 $3.5 $175,000
Sale
Common Stock 44,855 $26.62 $1,193,906
Option
Stock Option (Right to Buy) 50,000 $3.5 $175,000

Cerevel Therapeutics Holdings key executives

Cerevel Therapeutics Holdings, Inc. executives and other stock owners filed with the SEC: